PT - JOURNAL ARTICLE AU - THAMER, MAE AU - HERNÁN, MIGUEL A. AU - ZHANG, YI AU - COTTER, DENNIS AU - PETRI, MICHELLE TI - Prednisone, Lupus Activity, and Permanent Organ Damage AID - 10.3899/jrheum.080828 DP - 2009 Mar 01 TA - The Journal of Rheumatology PG - 560--564 VI - 36 IP - 3 4099 - http://www.jrheum.org/content/36/3/560.short 4100 - http://www.jrheum.org/content/36/3/560.full SO - J Rheumatol2009 Mar 01; 36 AB - Objective. To estimate the effect of corticosteroids (prednisone dose) on permanent organ damage among persons with systemic lupus erythematosus (SLE). Methods. We identified 525 patients with incident SLE in the Hopkins Lupus Cohort. At each visit, clinical activity indices, laboratory data, and treatment were recorded. The study population was followed from the month after the first visit until June 29, 2006, or attainment of irreversible organ damage, death, loss to follow-up, or receipt of pulse methylprednisolone therapy. We estimated the effect of cumulative average dose of prednisone on organ damage using a marginal structural model to adjust for time-dependent confounding by indication due to SLE disease activity. Results. Compared with non-prednisone use, the hazard ratio of organ damage for prednisone was 1.16 (95% CI 0.54, 2.50) for cumulative average doses > 0–180 mg/month, 1.50 (95% CI 0.58, 3.88) for > 180–360 mg/month, 1.64 (95% CI 0.58, 4.69) for > 360–540 mg/month, and 2.51 (95% CI 0.87, 7.27) for > 540 mg/month. In contrast, standard Cox regression models estimated higher hazard ratios at all dose levels. Conclusion. Our results suggest that low doses of prednisone do not result in a substantially increased risk of irreversible organ damage.